Skip to main content
. 2014 Aug 4;9(8):e104068. doi: 10.1371/journal.pone.0104068

Figure 7. Prognostic impact of immunohistochemical subtypes in DLBCL risk-stratified according to treatments.

Figure 7

(A, B) OS (A) and PFS (B) of all patients with GCB subtype or non-GCB subtype. (C, D) OS (C) and PFS (D) of CHOP-treated patients with GCB subtype or non-GCB subtype. (E, F) OS (E) and PFS (F) of R-CHOP-treated patients with GCB subtype or non-GCB subtype. OS, overall survival; PFS, progression-free survival; GCB, germinal center B-cell.